Download PDFPDF

270 Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address